RESUMEN
OBJECTIVES: Systemic thrombolysis improves outcomes in patients with pulmonary embolism (PE) but is associated with the risk of hemorrhage. The data on efficacy and safety of reduced-dose alteplase are limited. The study objective was to compare the characteristics, outcomes, and complications of patients with PE treated with full- or reduced-dose alteplase regimens. DESIGN: Multicenter retrospective observational study. SETTING: Tertiary care hospital and 15 community and academic centers of a large healthcare system. PATIENTS: Hospitalized patients with PE treated with systemic alteplase. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Pre- and post-alteplase hemodynamic and respiratory variables, patient outcomes, and complications were compared. Propensity score (PS) weighting was used to adjust for imbalances of baseline characteristics between reduced- and full-dose patients. Separate analyses were performed using the unweighted and weighted cohorts. Ninety-eight patients were treated with full-dose (100 mg) and 186 with reduced-dose (50 mg) regimens. Following alteplase, significant improvements in shock index, blood pressure, heart rate, respiratory rate, and supplemental oxygen requirements were observed in both groups. Hemorrhagic complications were lower with the reduced-dose compared with the full-dose regimen (13% vs. 24.5%, p = 0.014), and most were minor. Major extracranial hemorrhage occurred in 1.1% versus 6.1%, respectively ( p = 0.022). Complications were associated with supratherapeutic levels of heparin anticoagulation in 37.5% of cases and invasive procedures in 31.3% of cases. The differences in complications persisted after PS weighting (15.4% vs. 24.7%, p = 0.12 and 1.3% vs. 7.1%, p = 0.067), but did not reach statistical significance. There were no significant differences in mortality, discharge destination, ICU or hospital length of stay, or readmission after PS weighting. CONCLUSIONS: In a retrospective, PS-weighted observational study, when compared with the full-dose, reduced-dose alteplase results in similar outcomes but fewer hemorrhagic complications. Avoidance of excessive levels of anticoagulation or invasive procedures should be considered to further reduce complications.
Asunto(s)
Embolia Pulmonar , Activador de Tejido Plasminógeno , Humanos , Activador de Tejido Plasminógeno/efectos adversos , Estudios Retrospectivos , Embolia Pulmonar/complicaciones , Terapia Trombolítica/efectos adversos , Terapia Trombolítica/métodos , Hemorragia/complicaciones , Enfermedad Aguda , Anticoagulantes/uso terapéutico , Fibrinolíticos/efectos adversos , Resultado del TratamientoRESUMEN
INTRODUCTION: Optimal anticoagulation for left ventricular assist device recipients aims to balance thrombosis and bleeding complications. Routine plasma-based coagulation tests may not accurately reflect overall hemostasis, and surrogate markers are used to help guide clinicians in the diagnosis of pump thrombosis. Thromboelastography derived coagulation index (CI) has been shown to be a parameter that can reflect "normocoagulability" in mechanical circulatory support device patients, but there is minimal data with regard to outcomes available. Our aim was to determine the role of CI in predicting and defining suspected pump thrombosis in HeartMate II™ recipients. MATERIALS AND METHODS: We performed a single center, retrospective longitudinal cohort study with a nested case-control analysis to compare serial CI values over time in adult HeartMate II™ recipients who had confirmed or suspected pump thrombosis to those who did not. RESULTS AND CONCLUSIONS: A multivariate linear mixed model analysis of the suspected pump thrombosis versus no pump thrombosis groups found a significantly lower mean change in CI over time when recipients were followed for 24 months post-implant [0.71 (95% CI 0.1-1.32, p = .02)]; CI was first significant at six months. Within each arm, CI significantly decreased in the no pump thrombosis group, but did not significantly differ within the suspected pump thrombosis group. No significant differences were found between the two groups regarding the outcomes of death, transplant, or neurological events.
Asunto(s)
Corazón Auxiliar , Trombosis , Adulto , Corazón Auxiliar/efectos adversos , Humanos , Estudios Longitudinales , Estudios Retrospectivos , Tromboelastografía , Trombosis/diagnóstico , Trombosis/etiologíaRESUMEN
OBJECTIVE: To report on postoperative outcomes related to the administration of neostigmine for reversal of nondepolarizing neuromuscular blocking agents in cardiovascular surgery patients, with a specific focus on the duration of postoperative mechanical ventilation as the primary endpoint. DESIGN: A retrospective cohort study design was followed to achieve the study objectives. SETTING: This was a single-center, chart review study conducted at a large academic medical center of adult patients post-cardiovascular surgery. PARTICIPANTS: Patients were included if they had received a bolus dose of perioperative nondepolarizing neuromuscular blocking agent and underwent one of the targeted cardiovascular surgeries. INTERVENTIONS: Final analysis comprised of 175 patients, 95 of whom received neostigmine and 80 who did not receive neostigmine. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the duration of postoperative mechanical ventilation. When controlling for all covariates, neostigmine use was associated with a 0.34-hour reduction (â¼20.4 min) in duration of mechanical ventilation (parameter estimate: 0.66, 95% confidence interval 0.49-0.89; pâ¯=â¯0.0071). More patients who received neostigmine met the early extubation benchmark of less than 6 hours (55 v 34 patients; pâ¯=â¯0.04). Finally, neostigmine use was not found to be associated with increased risk of respiratory complications or postoperative nausea and/or vomiting. CONCLUSIONS: The use of neostigmine was found to have a protective effect on the duration of postoperative mechanical ventilation without increasing the risk of adverse complications.